Our Key Products



(daclatasvir tablets)

Download the Product Monograph
(daclatasvir tablets)

Read this carefully before you start taking DAKLINZA and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about DAKLINZA.

Serious Warningsand Precautions

Hepatitis B activity (e.g., inflamed liver) may increase when taking antiviral drugs like DAKLINZA, sometimes leading to liver failure and death (See “To help avoid side effects...” section Hepatitis B Reactivation).


What is DAKLINZA used for?

PrDAKLINZA is used to treat chronic (long-lasting) infection with the hepatitis C virus (HCV) genotypes 1, 2 and 3. DAKLINZA is used with other medicines that also treat chronic HCV infection.

People with hepatitis C infection have the virus in their blood and in their liver.

DAKLINZA should not be taken alone.

DAKLINZA has not been studied in children under 18 years of age.

How does DAKLINZA work?

PrDAKLINZA used with other medicines has been shown to cure chronic HCV infection in most patients. Cure means the HCV is removed from your blood (remains at an undetectable level) for 3 months after finishing all treatment.

DAKLINZA blocks a protein from the virus that is needed to make new virus, and this helps to lower the virus level in your body.

What are the ingredients in DAKLINZA?

Medicinal ingredients: Daclatasvir tablets, 30, 60 mg (as daclatasvir dihydrochloride).

Non-medicinal ingredients: Anhydrous lactose, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, Opadry Green and silicon dioxide. The Opadry Green contains the following inactive ingredients: FD & C blue #2 / indigo carmine aluminum lake, hypromellose, iron oxide (yellow), polyethylene glycol 400 and titanium dioxide.

DAKLINZA comes in the following dosage forms:

PrDAKLINZA is available as tablets. Each tablet contains daclatasvir as the active ingredient. Tablets are available in two strengths. DAKLINZA 60 mg tablets are light green, biconvex, pentagonal and debossed with "BMS" on one side and "215" on the other. DAKLINZA 30 mg tablets are green, biconvex, pentagonal and debossed with "BMS" on one side and "213" on the other.

Do not use DAKLINZA if:

  • you are allergic to daclatasvir or any other ingredients in this product (see "What are the ingredients in DAKLINZA")
  • you are taking certain medicines (see "Do not take DAKLINZA if you take a medicine that contains:")

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take DAKLINZA. Talk about any health conditions or problems you may have, including if you:

  • have liver problems other than hepatitis C infection.
  • have HIV-1.
  • have had a liver transplant.
  • have any other medical condition.
  • are pregnant or plan to become pregnant (see Pregnancy).
  • are breastfeeding or plan to breastfeed. It is not known if DAKLINZA passes into your breast milk. You and your healthcare provider should decide if you will take DAKLINZA or breastfeed. You should not do both.
  • are taking any medications (see Tell your healthcare professional about all medicines you take).
  • have a rare hereditary problem of galactose intolerance (severe lactase deficiency or glucose-galactose malabsorption) as this product contains lactose.

Hepatitis B Reactivation

Taking antiviral drugs such as DAKLINZA may increase hepatitis B activity. This can lead to liver problems such as liver failure and death. Contact your doctor if:

  • you have never been tested for hepatitis B.
  • you know you have a current hepatitis B infection.
  • you have had a previous hepatitis B infection.

Your healthcare professional may do blood tests:

  • before hepatitis C treatment.
  • to see the hepatitis B levels in your blood.
  • and may order hepatitis B treatment.

Heart block and a severe lowering of the heart beat have occurred in patients taking amiodarone with DAKLINZA and sofosbuvir. Your doctor will decide if amiodarone can be used with DAKLINZA and sofosbuvir. Contact your doctor if you suffer certain side effects while taking this combination (see “What are the possible side effects from using DAKLINZA?” section).

If you are taking DAKLINZA with sofosbuvir (SOVALDI), do not take other medicines that contain sofosbuvir, such as HARVONI.

Pregnancy and Birth Control

If you are pregnant or plan to become pregnant, ask your doctor for advice before taking this medicine. It is not known if DAKLINZA will harm your unborn baby.
DAKLINZA may be used with ribavirin. Ribavirin may cause birth defects and death of the unborn baby. Extreme care must be taken to avoid becoming pregnant.

  • Females must have a negative pregnancy test before starting DAKLINZA and ribavirin, every month while on the medicine, and for 6 months after stopping them.
  • You or your partner should not become pregnant while taking DAKLINZA with ribavirin and for 6 months after you have stopped taking them.
  • You and your partner must use 2 kinds of birth control while taking DAKLINZA and ribavirin and for 6 months after you have stopped taking them.
  • Talk to your doctor about the kind of birth control that you can use.
  • If you or your partner becomes pregnant while taking DAKLINZA and ribavirin or within 6 months after you stop taking them, tell your doctor right away.

Pregnancy when DAKLINZA is NOT taken with ribavirin:

If you are NOT taking ribavirin with DAKLINZA, the following information about pregnancy applies:

  • The effects of DAKLINZA on pregnancy and the unborn child are not known. DAKLINZA should not be used during pregnancy. If you can become pregnant, use effective birth control during and for 5 weeks after your treatment with DAKLINZA ends.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with DAKLINZA:

PrDAKLINZA and other medicines may affect each other. This can cause you to have too much or too little DAKLINZA or the other medicines in your body. The medicines may not work well or you may have side effects. Do not start taking a new medicine without talking to your healthcare provider or pharmacist.

Do not take DAKLINZA if you take a medicine that contains:

  • carbamazepine (Carbatrol♦, Epitol♦, Equetro♦, Tegretol) or oxcarbazepine (Oxtellar XR♦, Trileptal)
  • dexamethasone (when administered by injection or taken by mouth)
  • phenobarbital (Luminal♦)
  • phenytoin (Dilantin, Phenytek♦)
  • rifabutin (Mycobutin)
  • rifampin (Rifadin, Rifamate♦, Rifater, Rimactane♦)
  • rifapentine (Priftin♦)
  • St. John's wort (Hypericum perforatum) or a product that contains St. John's wort

Other drugs that may interact with DAKLINZA include:

  • amiodarone (Cordarone, Pacerone♦)
  • atazanavir (Reyataz)/ritonavir (Norvir), and atazanavir/cobicistat (Evotaz). You may need a lower dose of DAKLINZA.
  • atorvastatin (Caduet, Lipitor, Liptruzet♦)
  • boceprevir (Victrelis)
  • bosentan (Tracleer)
  • clarithromycin (Biaxin, Prevpac♦)
  • combination of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate (Stribild). You may need a lower dose of DAKLINZA.
  • dabigatran etexilate mesylate (Pradaxa)
  • digoxin (Digifab, Digox, Lanoxin)
  • ditiazem (Cardizem♦, Cardizem CD, Cardizem LA♦, Tiazac, Cartia XT♦, Dilacor XR♦, Dilt-CD♦, Diltzac♦, Taztia XT♦)
  • efavirenz (Sustiva, Atripla). You may need a higher dose of DAKLINZA.
  • etravirine (Intelence)
  • erythromycin
  • fluvastatin (Lescol)
  • itraconazole (Sporanox, Onmel♦)
  • ketoconazole (when taken by mouth) (Nizoral). You may need a lower dose of DAKLINZA.
  • modafinil (Provigil)
  • nafcillin♦
  • nevirapine (Viramune)
  • pitavastatin (Livalo♦)
  • posaconazole (Noxafil♦)
  • pravastatin (Pravachol)
  • rosuvastatin (Crestor)
  • simvastatin (Simcor♦, Vytorin♦, Zocor)
  • telaprevir (Incivek)
  • telithromycin (Ketek♦)
  • verapamil (Covera-HS♦, Calan♦, Verelan)
  • voriconazole

♦ Not marketed in Canada

This is not a complete list of medicines that could interact with DAKLINZA. Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.

How to take DAKLINZA:

Do not take PrDAKLINZA alone to treat chronic hepatitis C infection. DAKLINZA should be used together with other medicines for chronic HCV infection such as sofosbuvir (with or without ribavirin).

Take DAKLINZA exactly as your healthcare provider tells you to take it. Do not take more or fewer tablets than what your healthcare provider tells you to take.

Do not stop taking DAKLINZA without first talking with your healthcare provider.

Usual adult dose:

The usual dose is one 60 mg tablet once each day with or without food. A 30 mg tablet is available if your doctor prescribes a lower or higher dose.


If you think you have taken too much DAKLINZA, contact your healthcare professional, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

Missed Dose:

It is important not to miss a dose of PrDAKLINZA. If you do miss a dose and it is:

  • less than 20 hours from the time you usually take DAKLINZA, take the missed dose as soon as possible. Take the next dose at the usual time.
  • more than 20 hours from the time you usually take DAKLINZA, skip the missed dose. Take the next dose at the usual time.

Do not take 2 doses of DAKLINZA at the same time to make up for the missed dose.

What are possible side effects from using DAKLINZA?

These are not all the possible side effects you may feel when taking PrDAKLINZA. If you have any side effects not listed here, contact your healthcare professional. Please also see section "Do not use DAKLINZA if".

Daklinza in combination with sofosbuvir and amiodarone may cause serious side effects, including:

  • Slow heart rate (bradycardia). Get medical help right away if you take amiodarone with sofosbuvir and DAKLINZA and get any of the following symptoms:
    • Fainting or near fainting
    • weakness
    • chest pain
    • dizziness or lightheadedness
    • tiredness
    • confusion
    • not feeling well
    • shortness of breath
    • memory problems

When DAKLINZA is used in conjunction with sofosbuvir and ribavirin, common or very common side effects include headache, fatigue, nausea, rash, diarrhea and difficulty in sleeping.

The following serious effects have occurred:

Serious side effects and what to do about them
Symptom / effect* Talk to your healthcare professional Stop taking drug and get immediate medical help
Only if severe In all cases
Effect: Low red blood cell counts (anemia)
-Shortness of breath
-Looking pale

*These side effects are commonly associated with ribavirin therapy.

This is not a complete list of side effects. If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

Reporting Side Effects
You can help improve the safe use of health products for Canadians by reporting serious and unexpected side effects to Health Canada. Your report may help to identify new side effects and change the product safety information.
3 ways to report:
  • Online at MedEffect;
  • By calling 1-866-234-2345 (toll-free);
  • By completing a Consumer Side Effect Reporting Form and sending it by:
       - Fax to 1-866-678-6789 (toll-free), or
       - Mail to: Canada Vigilance Program
                        Health Canada, Postal Locator 1908C
                        Ottawa, ON
                        K1A 0K9
       - Postage paid labels and the Consumer Side Effect Reporting Form are available at MedEffect.
NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.


Store PrDAKLINZA at room temperature (15° to 30°C) in the original container.

Keep DAKLINZA and all medicines out of the reach and sight of children.

If you want more information about DAKLINZA:

  • Talk to your healthcare professional
  • Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website; the manufacturer's website http://www.bmscanada.ca, or by calling 1-866-463-6267.

This leaflet was prepared by Bristol-Myers Squibb Canada

Last Revised May 26, 2017

DAKLINZA is a registered trademark of Bristol-Myers Squibb Holdings Ireland used under licence by Bristol-Myers Squibb Canada.

Other brands listed are trademarks of their respective owners.